Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib for relapsed small cell lung cancer vs placebo (phase II)
CTR20170146Phase 2Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in small cell lung cancer (SCLC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Feb 2017; status: completed.
02
Drugs
anlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20170146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170146.